Post-earnings recap
Reported
Tue, Aug 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a narrower-than-expected loss per share, which pleased investors and led to a stock increase of 3.64%. The company did not provide revenue figures or future guidance, but management's positive comments about their clinical trials suggest potential growth ahead. Investors may view the EPS beat as a sign of improving operational efficiency.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | +12.65% |
| Revenue | N/A | N/A | N/A |
Management expressed optimism about ongoing projects and their potential impact. However, they did not provide specific guidance for future performance.
Management highlighted progress in their clinical trials.
They emphasized a commitment to advancing their pipeline.
No specific guidance was provided for future quarters.